What This Article Covers
This article summarizes published research on Bofanglutide-HRS9531 for technical review. It separates direct human evidence, review-level context, and animal or mechanistic work so the reader can see what has actually been tested before seeing the limitations.
The available evidence set contains three primary human-study publications that explicitly name bofanglutide: a placebo-controlled phase 2b trial in Chinese adults with overweight or obesity, a phase 2b comparison with semaglutide in Chinese patients with type 2 diabetes, and an oral pharmacokinetic and pharmacodynamic study in healthy Chinese participants. [pubmed:41760612] [pubmed:42372276] [pubmed:42442555]
These publications establish that bofanglutide has undergone human investigation in several defined settings. The evidence set does not, however, include effect sizes, confidence intervals, adverse-event frequencies, or other numerical results sufficient to independently characterize efficacy or safety.
The evidence set also contains references concerning GZR18 and a conference abstract with unresolved terminology for HRS9531. Those sources require separate treatment and should not be used to expand the direct evidence for bofanglutide.
Bottom Line
Published human research in the evidence set covers bofanglutide in adults with overweight or obesity, patients with type 2 diabetes, and healthy participants receiving an oral formulation. The studies address clinical outcomes or pharmacology in their respective settings, but the evidence set does not supply their numerical findings. It therefore cannot establish how large any clinical effect was, whether bofanglutide compared favorably with another treatment, or whether safety findings generalize across populations, formulations, and treatment durations.
The literature summarized here does not justify dosing guidance or broad safety conclusions. Studied schedules and formulations should not be interpreted as recommended regimens, and tolerability should not be inferred beyond the populations and conditions actually evaluated.
What Was Tested in Humans?
Phase 2b study in adults with overweight or obesity
A randomized, double-blind, placebo-controlled phase 2b trial evaluated bofanglutide in Chinese adults with overweight or obesity. Its publication title identifies bofanglutide as a GLP-1 receptor agonist. The citation establishes direct clinical investigation in this population, but the synthesis evidence set does not provide endpoint definitions, effect estimates, statistical results, or adverse-event frequencies. [pubmed:41760612]
The study’s existence is not, by itself, proof of clinically meaningful benefit or generalized safety. Conclusions about weight-related outcomes must await examination of the primary report’s numerical findings.
Phase 2b study in type 2 diabetes
A separate phase 2b randomized clinical trial compared weekly and biweekly bofanglutide with semaglutide in Chinese patients with type 2 diabetes. [pubmed:42372276]
The citation establishes an active-comparator trial in a defined diabetes population. Within the supplied evidence set, it does not establish superiority, noninferiority, the magnitude of glycemic effects, or applicability outside the studied population. The schedules named in the title document the trial design; they are not dosing guidance.
Oral pharmacology study in healthy participants
A human study evaluated single and multiple administrations of oral bofanglutide co-formulated with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) in healthy Chinese participants. Its stated scope included safety, tolerability, relative bioavailability, pharmacokinetics, and pharmacodynamics. [pubmed:42442555]
This study concerns an oral formulation and healthy participants. It should not be treated as interchangeable with clinical outcome trials in people with overweight, obesity, or type 2 diabetes. The evidence set also provides no numerical pharmacokinetic, pharmacodynamic, or tolerability results from which to draw broader conclusions.
Evidence map
| Citation | Study context | What the evidence set establishes | What it does not establish | |—|—|—|—| | [pubmed:41760612] | Phase 2b placebo-controlled trial in Chinese adults with overweight or obesity | Direct human investigation of bofanglutide | Effect size, statistical findings, or generalized safety | | [pubmed:42372276] | Phase 2b comparison with semaglutide in Chinese patients with type 2 diabetes | Direct comparative clinical investigation | Superiority, noninferiority, or a recommended regimen | | [pubmed:42442555] | Oral PK/PD and bioavailability study in healthy Chinese participants | Direct study of an oral bofanglutide formulation | Clinical efficacy in patient populations or equivalence with other formulations |
All three reported human-study contexts involve Chinese participants. The evidence set does not establish whether findings transfer to other populations, so external generalization should remain limited.
What Do Reviews and Evidence Syntheses Add?
The synthesis evidence set reports no formal review sources. Although reviews can help place a compound within a broader mechanistic and translational literature, no review article is available here to support such an account.
The oral PK/PD study and the type 2 diabetes trial are primary human investigations, not review articles. [pubmed:42442555] [pubmed:42372276] They should be cited according to their actual study roles rather than used as review-level evidence.
What Did Animal and Mechanistic Studies Show?
The evidence set reports no preclinical sources. It therefore does not support a preclinical account of bofanglutide’s mechanism, nor can mechanistic plausibility be used here to infer clinical utility.
One primary publication title calls bofanglutide a GLP-1 receptor agonist. [pubmed:41760612] A separate conference abstract citation describes HRS9531 as a GLP-1/GIP dual agonist in Chinese patients with overweight or obesity and polycystic ovary syndrome. [crossref:10.2337/db26-1815-p]
That conference/abstract citation presents an unresolved nomenclature or pharmacologic-classification issue within the evidence set. It is insufficient to reclassify bofanglutide in this summary and does not supply primary numerical results for evaluation here.
How the Evidence Fits Together
The practical reading for Bofanglutide-HRS9531 is evidence hierarchy. Human studies, when present, carry the most weight, but only for the exact population, route, comparator, and endpoint studied. Reviews can help map the field, and animal or mechanistic studies can explain biological plausibility, but neither should be used to leap beyond the human evidence.
What Is Not Established
- Broad human efficacy for Bofanglutide-HRS9531 is not established by this article.
- Animal, cellular, or review-level findings should not be converted into human-use claims.
- Dosing, administration, treatment, diagnostic, or veterinary-use guidance is outside the scope of KRL materials.
Research-Use Boundary
This article summarizes published research and regulatory-source discussion for technical review. It is not medical advice, not a dosing guide, and not a recommendation for human or veterinary use. KRL materials are sold for research use only and are not for diagnostic, therapeutic, or administration purposes.
Selected Sources
- *Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.* Published February 2, 2026. PubMed
- *Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes: A Phase 2b Randomized Clinical Trial.* Published June 3, 2026. PubMed
- *Safety, tolerability, relative bioavailability, pharmacokinetics, and pharmacodynamics of single and multiple doses of the novel oral bofanglutide in healthy Chinese participants.* Published July 1, 2026. PubMed
- *1815-P: Efficacy and Safety of the GLP-1/GIP Dual Agonist HRS9531 in Overweight/Obese Chinese Patients with Polycystic Ovary Syndrome.* Conference abstract citation, published June 5, 2026. DOI
- *GZR18, a GLP-1 analog with once-weekly or bi-weekly dosing for body weight management: A randomized, placebo-controlled, phase 1b/2a trial.* Background analog reference; published April 2, 2026. PubMed
- *Safety and efficacy of GZR18, a long-acting GLP-1 analog, in Chinese patients with type 2 diabetes: A randomized, double-blind, phase 1b/2a trial.* Background analog reference; published July 2, 2026. PubMed
Related KRL Resources
Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.
1st Time Customers Receive 10% off their 1st order over $100.00 with CODE KRL10
Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.